ThromboGenics and BioInvent Publicate Data on a Novel Class of Angiogenesis Inhibitors
Novel anti-PlGF antibody, TB-403, being developed by ThromboGenics and BioInvent for
05-Nov-2007 -
ThromboGenics NV and co-development partner, BioInvent International, announced the publication of data that highlight for the first time the therapeutic potential of anti-PlGF agents to treat cancer based on research performed at the University of Leuven, Belgium and the Flanders Institute for ...
angiogenesis
antibodies
Belgium
+10